PRISMA HEALTH-UPSTATE

Cereno Scientific announces positive Phase IIa trial results for CS1 in Pulmonary Arterial Hypertension, showing safety, tolerability, and positive impact on risk score, functional class, and mean pulmonary arterial pressure. The data supports CS1's potential as a disease-modifying therapy, prompting discussions with regulatory authorities for a pivotal trial.